TMCnet News
Small-Cell Lung Cancer - Pipeline Review, H2 2017 - Research and MarketsThe "Small-Cell Lung Cancer - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Small-Cell Lung Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeuticsunder Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 10, 49, 28, 2, 35 and 7 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively. Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/research/7m623d/smallcell_lung?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20171207005872/en/ |
